Literature DB >> 7815555

Characterization of the CD48 gene demonstrates a positive element that is specific to Epstein-Barr virus-immortalized B-cell lines and contains an essential NF-kappa B site.

L D Klaman1, D A Thorley-Lawson.   

Abstract

Epstein-Barr virus (EBV) infection of mature, resting B cells drives them to become lymphoblasts expressing high levels of cell surface molecules, such as CD48, characteristically expressed on normal activated B cells. Here, we report on the identification of an enhancer element in the CD48 gene which reproducibly confers strong transcriptional activity only in EBV-positive B-lymphoblastoid cell lines. The element is not activated upon infection of established EBV-negative B-cell lines, indicating that EBV fails to drive these cells to a fully lymphoblastoid phenotype. An NF-kappa B binding site is an essential component of the element but alone is not sufficient to account for the activity or the specificity of the element. We have detected a specific nuclear protein complex that binds to the element and show that NF-kappa B1 (p50) is a part of this complex. The EBV-encoded latent membrane protein 1 is capable of transactivating the isolated CD48 NF-kappa B site but not the intact element, suggesting that the latent membrane protein 1-driven activation of NF-kappa B/Rel must interact with other regulatory pathways to control expression of cellular genes as EBV drives resting B cells into the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815555      PMCID: PMC188654     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMP.

Authors:  R Moorthy; D A Thorley-Lawson
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity.

Authors:  D Wang; D Liebowitz; F Wang; C Gregory; A Rickinson; R Larson; T Springer; E Kieff
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

3.  The involvement of NF-kappa B in beta-interferon gene regulation reveals its role as widely inducible mediator of signal transduction.

Authors:  M J Lenardo; C M Fan; T Maniatis; D Baltimore
Journal:  Cell       Date:  1989-04-21       Impact factor: 41.582

4.  B cell proliferation in follicles, germinal centre formation and the site of neoplastic transformation in Burkitt's lymphoma.

Authors:  I C MacLennan; Y L Liu; N R Ling
Journal:  Curr Top Microbiol Immunol       Date:  1988       Impact factor: 4.291

5.  Identification of regulatory elements of cloned genes with functional assays.

Authors:  N Rosenthal
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.

Authors:  K M Kaye; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

7.  Activation and infection of B cells by Epstein-Barr virus. Role of calcium mobilization and of protein kinase C translocation.

Authors:  B Dugas; J F Delfraissy; A Calenda; M Peuchmaur; C Wallon; M T Rannou; P Galanaud
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

8.  Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes.

Authors:  W Hammerschmidt; B Sugden
Journal:  Nature       Date:  1989-08-03       Impact factor: 49.962

9.  EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.

Authors:  P D Ling; J J Hsieh; I K Ruf; D R Rawlins; S D Hayward
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Functionally distinct NF-kappa B binding sites in the immunoglobulin kappa and IL-2 receptor alpha chain genes.

Authors:  S L Cross; N F Halden; M J Lenardo; W J Leonard
Journal:  Science       Date:  1989-04-28       Impact factor: 47.728

View more
  7 in total

1.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis.

Authors:  A K Tai; E J O'Reilly; K A Alroy; K C Simon; K L Munger; B T Huber; A Ascherio
Journal:  Mult Scler       Date:  2008-08-13       Impact factor: 6.312

3.  Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn.

Authors:  Coralie Bloch-Queyrat; Marie-Claude Fondanèche; Riyan Chen; Luo Yin; Francis Relouzat; André Veillette; Alain Fischer; Sylvain Latour
Journal:  J Exp Med       Date:  2005-07-04       Impact factor: 14.307

4.  ORMDL3 promotes eosinophil trafficking and activation via regulation of integrins and CD48.

Authors:  Sung Gil Ha; Xiao Na Ge; Nooshin S Bahaie; Bit Na Kang; Amrita Rao; Savita P Rao; P Sriramarao
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection.

Authors:  Chibueze Chioma Ezinne; Makoto Yoshimitsu; Yohann White; Naomichi Arima
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

6.  The response of porcine monocyte derived macrophages and dendritic cells to Salmonella Typhimurium and lipopolysaccharide.

Authors:  Kamila Kyrova; Hana Stepanova; Ivan Rychlik; Ondrej Polansky; Lenka Leva; Zuzana Sekelova; Martin Faldyna; Jiri Volf
Journal:  BMC Vet Res       Date:  2014-10-01       Impact factor: 2.741

7.  Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy.

Authors:  Loris Zamai; Genny Del Zotto; Flavia Buccella; Sara Gabrielli; Barbara Canonico; Marco Artico; Claudio Ortolani; Stefano Papa
Journal:  Cells       Date:  2020-03-19       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.